TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04848246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: This group received Bupropion 150 mg twice daily for 10 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural Change Communication
Description: This group will receive Behavioural Change Communication

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural Change Communication
Description: This group will receive Behavioural Change Communication
Study: NCT05804253

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Maxillary sinus augmentation
Description: Maxillary sinus grafting with 2 different xenogenic materials

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Maxillary sinus augmentation
Description: Maxillary sinus grafting with 2 different xenogenic materials
Study: NCT03630029

Intervention type: DRUG
Group type: OTHER
Intervention: FeS and SnPP
Description: Escalating doses of drug will be compared for biomarker changes

Intervention type: DRUG
Group type: OTHER
Intervention: FeS and SnPP
Description: Escalating doses of drug will be compared for biomarker changes

Intervention type: DRUG
Group type: OTHER
Intervention: FeS and SnPP
Description: Escalating doses of drug will be compared for biomarker changes

Intervention type: DRUG
Group type: OTHER
Intervention: FeS and SnPP
Description: Escalating doses of drug will be compared for biomarker changes
Study: NCT03017547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IC14
Description: Blocks CD14 signalling which is responsible for disease pathogenesis in ARDS

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sterile normal saline for infusion
Study: NCT02131727

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hand Hygiene Improvement Intervention
Description: Participants received a 4 minute video about protective hand hygiene behaviors and other activities (cough ettiquette, and staying home when ill) to reduce the risk of contracting respiratory tract and GI infections. In addition, motivational posters and hand hygiene supplies were distributed in the work setting.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Ask Me 3
Description: Participants in the control group received a 4 minute training video about the Ask Me 3 program to promote effective communication with health care providers, along with an Ask Me 3 brochure and a key-chain with the Ask Me 3 principles for effective communication with health care providers.
Study: NCT03265015

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Habit Override Practice
Description: Computerized brain training to provide practice in overriding avoidance habits.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Habit Override Practice
Description: Computerized brain training to provide practice in overriding avoidance habits.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: Non-invasive method for temporary, focal stimulation of brain areas.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: Non-invasive method for temporary, focal stimulation of brain areas.
Study: NCT03712449

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JUVÉDERM®
Description: Facial filler injection (JUVÉDERM VOLBELLA with Lidocaine, and/or JUVÉDERM VOLIFT with Lidocaine, and/or JUVÉDERM VOLUMA with Lidocaine, and/or JUVÉDERM VOLITE with Lidocaine) from Month 6 to Month 8 (BELKYRA Treatment) and Month 0 to Month 2 (Non-BELKYRA Treatment).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JUVÉDERM®
Description: Facial filler injection (JUVÉDERM VOLBELLA with Lidocaine, and/or JUVÉDERM VOLIFT with Lidocaine, and/or JUVÉDERM VOLUMA with Lidocaine, and/or JUVÉDERM VOLITE with Lidocaine) from Month 6 to Month 8 (BELKYRA Treatment) and Month 0 to Month 2 (Non-BELKYRA Treatment).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOTOX Cosmetic®
Description: BOTOX Cosmetic, 20 U to glabellar lines and/or 2-6 U injected bilaterally to crow's feet lines and/or 24 U injected to forehead lines at Month 9 and Month 10 (BELKYRA Treatment) and at Month 3 and Month 4 (Non-BELKYRA Treatment).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOTOX Cosmetic®
Description: BOTOX Cosmetic, 20 U to glabellar lines and/or 2-6 U injected bilaterally to crow's feet lines and/or 24 U injected to forehead lines at Month 9 and Month 10 (BELKYRA Treatment) and at Month 3 and Month 4 (Non-BELKYRA Treatment).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BELKYRA®
Description: BELKYRA, subcutaneous injection for maximum of 6 treatments, 1 month apart from Month 0 to Month 5. Maximum dose = 100 mg (10mL).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SkinMedica
Description: SkinMedica products (Facial Cleanser, TNS Essential Serum®, Rejuvenative Moisturizer, Optional: Total Defense + Repair Broad Spectrum Sunscreen SPF34), applied daily from Month 6 to Month 11 (BELKYRA Treatment) and Month 0 to Month 5 (Non-BELKYRA Treatment).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SkinMedica
Description: SkinMedica products (Facial Cleanser, TNS Essential Serum®, Rejuvenative Moisturizer, Optional: Total Defense + Repair Broad Spectrum Sunscreen SPF34), applied daily from Month 6 to Month 11 (BELKYRA Treatment) and Month 0 to Month 5 (Non-BELKYRA Treatment).
Study: NCT04083924

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Basic cardiac ultrasound training with Butterfly iQ handheld ultrasound
Description: Pre-training online module of the American society of Echocardiography and hands-on training of basic cardiac ultrasound with Butterfly iQ handheld ultrasound.
Study: NCT03630029

Intervention type: DRUG
Group type: OTHER
Intervention: FeS and SnPP
Description: Escalating doses of drug will be compared for biomarker changes
Study: NCT01620333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 50
Description: A single dose of 0.08 U/kg body weight, administered subcutaneously (s.c., under the skin) on two dosing visits in random order separated by 6-12 days
Study: NCT05256212

Intervention type: OTHER
Intervention: exposure to environmental contaminants
Description: to measure levels of contaminants in different matrixes
Study: NCT02706951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Capsule; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Capsule; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Upadacitinib
Description: Tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Upadacitinib
Description: Tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Methotrexate
Description: Capsule; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Methotrexate
Description: Capsule; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Methotrexate
Description: Capsule; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Methotrexate
Description: Capsule; Oral
Study: NCT02516865

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitbit activity tracker
Description: Tracks steps taken, floors climbed, and distance traveled. Sleep quality is an additional measurement.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitbit activity tracker
Description: Tracks steps taken, floors climbed, and distance traveled. Sleep quality is an additional measurement.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ankle weights
Description: Worn during typical daily activities.
Study: NCT03158129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Given IV
Study: NCT03801681

Intervention type: DIAGNOSTIC_TEST
Intervention: ECG holter monitoring
Description: patients will be monitored using ECG-holter
Study: NCT03287778

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pyridoxine
Description: Max dose of 400 mg QD PO

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebos will be administered.
Study: NCT01476813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Description: comparison of different dosages of drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Description: comparison of different dosages of drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Description: comparison of different dosages of drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator
Description: comparison of different dosages of drug versus comparator
Study: NCT05512078

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bone positioning surgical guide
Description: patient specific surgical positioning guide made from acrylonitrile butadiene styrene (ABS) plastic material.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone positioning surgical guide
Description: patient specific surgical positioning guide made from acrylonitrile butadiene styrene (ABS) plastic material.
Study: NCT03016598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Description: Each Veteran with a stimulant use disorder, receiving MMT for OUD will receive a oxytocin nasal spray 40 International Units (IU) to be self administered twice daily over 6 weeks while in the MMT program. The veteran will come in for a total of 7 weekly visits. At baseline and during the last visit the veteran will complete at Trier Social Stress Test (TSST), and psychophysiological and biomarkers of stress will be collected. At every weekly visit a urine sample and self-reported drug use will be collected and therapy attendance will be recorded.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal placebo
Description: Each Veteran with a stimulant use disorder, receiving MMT for OUD will receive a placebo nasal spray 40IU to be self administered twice daily over 6 weeks while in the MMT program. The veteran will come in for a total of 7 weekly visits. At baseline and during the last visit the veteran will complete at Trier Social Stress Test (TSST), and psychophysiological and biomarkers of stress will be collected. At every weekly visit a urine sample and self-reported drug use will be collected and therapy attendance will be recorded.
Study: NCT00704171

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Tissue Closure Techniques
Description: Standard Tissue Closure Techniques (sutures and staples only)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PleuraSeal Lung Sealant System

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PleuraSeal Lung Sealant System
Study: NCT01620333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 50
Description: A single dose of 0.08 U/kg body weight, administered subcutaneously (s.c., under the skin) on two dosing visits in random order separated by 6-12 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 70
Description: A single dose of 0.08 U/kg body weight, administered subcutaneously (s.c., under the skin) on two dosing visits in random order separated by 6-12 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 70
Description: A single dose of 0.08 U/kg body weight, administered subcutaneously (s.c., under the skin) on two dosing visits in random order separated by 6-12 days
Study: NCT04239196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab and IV steroids combination
Description: Every patient will receive the reference treatment for GCA with ocular complication, i.e. high dose corticosteroid therapy (intravenous pulses of 7,5 to 15 mg/kg/day of methylprednisolone with an upper limit of 1000 mg/day for 3 days followed by oral prednisone at 1 mg/kg/day with progressive decrease as usually done) and aspirin 75 mg/day. The mean duration of this reference treatment is 18 months.~Patients will receive in addition to the reference treatment four subcutaneous injections of tocilizumab 162 mg over one month (1 injection per week).

Intervention type: OTHER
Group type: OTHER
Intervention: IV steroids combination alone
Description: Every patient will receive the reference treatment for GCA with ocular complication, i.e. high dose corticosteroid therapy (intravenous pulses of 7,5 to 15 mg/kg/day of methylprednisolone with an upper limit of 1000 mg/day for 3 days followed by oral prednisone at 1 mg/kg/day with progressive decrease as usually done) and aspirin 75 mg/day. The mean duration of this reference treatment is 18 months.
Study: NCT00534417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Capecitabine will be given on a continuous basis at a total dose of 1500 mg, given as 1000 mg po in the morning (AM) and 500 mg po in the evening (PM) in patients of body weight \< 80 Kg, and at a total dose of 2000 mg given as 1000 mg po bid in patients with a body weight of ≥80 Kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fulvestrant
Description: Fulvestrant will be given at 500mg on Day 1 followed by 250 mg on Days 15 and 29, then 250mg every 28 days(Q28d).
Study: NCT00639977

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: 20-minute session of acupuncture with needles inserted in specific points: Tong Zi Liao, Yang Bai and Jing Ming

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: 20- minute session of acupuncture with needles inserted in false points allocated 1 cm from the true points in areas without acupuncture's meridians
Study: NCT02057575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PG324 Ophthalmic Solution 0.01%
Description: 1 drop in the evening (PM), once daily (QD), both eyes (OU)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PG324 Ophthalmic Solution 0.02%
Description: 1 drop in the evening (PM), once daily (QD), both eyes (OU)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Netarsudil (AR-13324) Ophthalmic Solution 0.02%
Description: 1 drop in the evening (PM), once daily (QD), both eyes (OU)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost Ophthalmic Solution 0.005%
Description: 1 drop in the evening (PM), once daily (QD), both eyes (OU)
Study: NCT04092049

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lollipop
Description: chewing lollipop for 10 minutes
Study: NCT03732976

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified ramped position
Description: This position will be achieved using a special pillow. Shoulders will be elevated and neck will be extended to bring the breasts away from the laryngoscopy. The patient will be positioned so that the tip of the last spinous process (C7) will be at the edge of the pillow. The neck will be extended to the most possible range.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ramped position
Description: This position will be achieved by elevation of the shoulders and the head elevation till achieving alignment of sternal notch and external auditory meatus
Study: NCT03548493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate
Description: Magnesium sulphate will be given to the experimental group in a dose of 50mg/kg IV over 15 minutes followed by continuous infusion at 15 mg/kg/h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl will be given to the active comparator group in a dose of 1 μg /kg IV bolus over 15 minutes followed by continuous infusion starting at 0.5 μg /kg/h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: In both groups Fentanyl and magnesium sulphate will be accompanied by IV propofol at a dose of 50- 150 μg /kg) bolus over 15 minutes to achieve target sedation level, that is Ramsay sedation scale (RSS) 3,if RSS afterwards does not reach 3, a supplementary bolus dose of 0.2 mg/kg propofol will be given to the patients, followed by ( 20-40 μg /kg/ min) to maintain Intraoperative level of sedation by bispectral index (BIS ) reading by 60-80%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: In both groups Fentanyl and magnesium sulphate will be accompanied by IV propofol at a dose of 50- 150 μg /kg) bolus over 15 minutes to achieve target sedation level, that is Ramsay sedation scale (RSS) 3,if RSS afterwards does not reach 3, a supplementary bolus dose of 0.2 mg/kg propofol will be given to the patients, followed by ( 20-40 μg /kg/ min) to maintain Intraoperative level of sedation by bispectral index (BIS ) reading by 60-80%
Study: NCT02876029

Intervention type: OTHER
Group type: OTHER
Intervention: Reference
Description: the reference product used

Intervention type: OTHER
Group type: OTHER
Intervention: Reference
Description: the reference product used

Intervention type: OTHER
Group type: OTHER
Intervention: Test product
Description: The test Product used

Intervention type: OTHER
Group type: OTHER
Intervention: Test product
Description: The test Product used
Study: NCT02906280

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EBUS-TBNA needle
Description: tissue sampling

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EBUS-TBNA needle
Description: tissue sampling
Study: NCT03662646

Intervention type: OTHER
Intervention: no intervention performed- observational only
Description: no intervention performed- observational only

Intervention type: OTHER
Intervention: no intervention performed- observational only
Description: no intervention performed- observational only
Study: NCT02066610

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: selenium and sodium selenate supplementation
Description: Parenteral nutrition with selenium and sodium selenate supplementation of infant formula

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: selenium and sodium selenite supplementation
Description: Parenteral nutrition with selenium and sodium selenite supplementation of infant formula

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Without selenium and sodium selenate supplementation
Description: Parenteral nutrition without selenium and sodium selenate supplementation of infant formula

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Without selenium and sodium selenite supplementation
Description: Parenteral nutrition without selenium and sodium selenite supplementation of infant formula
Study: NCT01003145

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza A (H1N1) 2009 monovalent vaccine, inactivated

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza A (H1N1) 2009 monovalent vaccine, inactivated

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza A (H1N1) 2009 monovalent vaccine, inactivated
Study: NCT00766402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol /acetaminophen
Description: Participants will receive a combination tablet of 37.5 milligram (mg) tramadol and 325 mg acetaminophen, orally twice daily up to 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Description: Participants will receive 50 mg diclofenac tablet, orally twice daily up to 8 weeks.
Study: NCT01007006

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMRDU
Description: The TMRDU will assist study subjects with taking their medications as prescribed by notifying them when the next dose is due and tracking whether and when it was taken.
Study: NCT03771222

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prophylactic DLI
Description: The G-CSF-mobilized PBSCs from cryopreserved cells of the graft were infused to the recipient at a dose of 2X10\^7 CD3+ cells/kg recipient body weight. Decitabine (10 mg/m2, days 1 to 5) followed by prophylactic DLI would be given to those patients carrying TET2, DNMT3a or TP53 gene mutations.
Study: NCT01636583

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LSF water without meal
Description: Composition of test meal: 67Zn-labelled LSF-fortified water (1 mg 67Zn as ZnSO4 + 1 mg of eluted Zn from LSF device of natural isotopic composition)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LSF water and inhibitory meal
Description: Composition of test meal: Maize porridge and 67Zn-labelled LSF-fortified water (1 mg 67Zn as ZnSO4 + 0.44 mg of eluted Zn from LSF device of natural isotopic composition)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fortified inhibitory meal with water
Description: Composition of test meal: Maize porridge (1 mg 67Zn as ZnSO4 + 0.44 mg Zn as ZnSO4 of natural isotopic composition) and high purity water